Clinical use of nafarelin in the treatment of leiomyomas: A review of the literature

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 45, Issue 6, 2000, Pages 481-489

  Minaguchi, Hiroshi ^a   Wong, Josephine M ^b   Snabes, Michael C ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b GD Searl and Co   (United States)

Author keywords

Anemia; Dysmenorrhea; Leiomyoma; Menorrhagia; Nafarelin; Pelvic pain

Indexed keywords

ESTROGEN; HEMOGLOBIN; NAFARELIN; NAFARELIN ACETATE;

ARTICLE; CLINICAL TRIAL; ESTROGEN SYNTHESIS; FEMALE; HOT FLUSH; HUMAN; LEIOMYOMA; MENORRHAGIA; PRIORITY JOURNAL;

ABDOMINAL PAIN; CLINICAL TRIALS; FEMALE; HORMONES; HUMANS; LEIOMYOMA; MENORRHAGIA; NAFARELIN; PREGNANCY; UTERINE NEOPLASMS;

EID: 0033921721     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Moghissi KS: Hormonal therapy before surgical treatment for uterine leiomyomas. Gynecol Obstet 1991;172:497-502
2. Hutchins FL Jr: Uterine fibroids: Diagnosis and indications for treatment. Obstet Gynecol Clin North Am 1995;22: 659-665
3. Andreyko JA, Blumenfeld Z, Marshall LA, et al: Use of agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: Assessment by magnetic resonance imaging. Am J Obstet Gynecol 1988;158:903-910
4. Shaw RW: Mechanism of LHRH analogue action in uterine fibroids. Horm Res (suppl 1) 1989;32:150-153
5. Friedman AJ, Lobel SM, Rein MS, et al: Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesis. Am J Obstet Gynecol 1990;163: 1114-1119
6. Williams IA, Shaw R: Effect of nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol 1990;34:111-117
7. Cann CE, Henzel M, Barry K, et al: Reversible bone loss is produced by the GnRH agonist nafarelin. In Calcium Regulation and Bone Metabolism: Basic and Clinical Aspects: Proceedings from the Ninth International Conference on Calcium Regulating Hormones and Bone Metabolism. Edited by DV Cohn, TJ Martin, PJ Meunier. Nice, October 25-November 1,1986, Amsterdam, Elsevier, 1987, pp 123-127
8. Ylikorkala O, Tiitinen A, Hulkko S, et al: Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: A placebo-controlled, double-blind study. Hum Reprod 1995;10:1470-1474
9. Minaguchi H, Kobayashi T, Taketani Y, et al: Clinical evaluation of nafarelin acetate nasal spray in patients with uterine myoma: Results of a dose-dependent study (Phase II). J Clin Ther Med 1997;13:25-70
10. Minaguchi H, Kobayashi T, Taketani Y, et al: A double-blind study of nafarelin acetate (RS-94991) nasal spray versus buserelin acetate for uterine myomas (Phase III). J Clin Ther Med 1997;13:1493-1532
11. Golan A: GnRH analogues in the treatment of uterine fibroids. Hum Reprod (suppl 3) 1996;11:33-41
12. Broekmans FJ: GnRH agonists and uterine leiomyomas. Hum Reprod (suppl 3) 1996;11:3-25
13. Davis KM, Schlaff WD: Medical management of uterine fibromyomata. Obstet Gynecol Clin North Am 1995;22: 727-738
14. Agarwal SK, Hamrang C, Henzl MR, et al: Nafarelin vs. leuprolide acetate depot for endometriosis: Changes in bone mineral density and vasomotor symptoms. J Reprod Med 1997;42:413-423
15. Crosignani PG, Bramante T, Oldani S, et al: GnRH agonists before surgery for uterine leiomyomas: A review. J Reprod Med 1996;41:415-421
16. Donnez J, Mathieu PE, Bassil S, et al: Laparoscopic myomectomy today: Fibroids: Management and treatment: The state of the art. Hum Reprod 1996;11:1837-1840